P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB

• Jorge Cortes,
• Michael Deininger,
• Elza Lomaia,
• Beatriz Moiraghi,
• Soledad Undurraga,
• Carolina Pavlovsky,
• Charles Chuah,
• Tomasz Sacha,
• Jeffrey H. Lipton,
• James Mccloskey,
• Philippe Rousselot,
• Gianantonio Rosti,
• Hugues de Lavallade,
• Christine Rojas,
• Anna Turkina,
• Moshe Talpaz,
• Michael Mauro,
• Vickie Lu,
• Alexander Vorog,
• Jane Apperley

Affiliations

Jorge Cortes

1 Georgia Cancer Center

Michael Deininger

2 Versiti Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI

Elza Lomaia

3 Almazov National Medical Research Centre, St. Petersburg, Russia

Beatriz Moiraghi

4 Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina

Soledad Undurraga

5 Hospital del Salvador, Santiago, Chile

Carolina Pavlovsky

6 Fundaleu, Buenos Aires, Argentina

Charles Chuah

7 Singapore General Hospital, Duke-NUS Medical School, Singapore, Singapore

Tomasz Sacha

8 Jagiellonian University Hospital in Krakow, Krakow, Poland

Jeffrey H. Lipton

9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

James Mccloskey

10 The John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, United States

Philippe Rousselot

11 Centre Hospitalier de Versailles University de Versailles Saint-Quentin-en-Yvelines, Paris, France

Gianantonio Rosti

12 IRST/IRCCS “Dino Amadori”, Meldola (FC), Italy

Hugues de Lavallade

13 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Christine Rojas

14 Centro de Investigaciones Clinicas Vina del Mar, Valparaíso, Chile

Anna Turkina

15 National Medical Research Center for Hematology, Moscow, Russia

Moshe Talpaz

16 Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, United States

Michael Mauro

17 Memorial Sloan Kettering, New York, New York, NY, United States

Vickie Lu

18 Takeda Development Center Americas, Inc., Lexington, MA, United States

Alexander Vorog

18 Takeda Development Center Americas, Inc., Lexington, MA, United States

Jane Apperley

19 Imperial College London, London, United Kingdom